Claim OwnershipListen to Gynecologic Oncology
Subscribed: 27Played: 172
Subscribe
© 2023 Elsevier Ltd.
Description
Listen to the latest news from the experts in your field.
41 Episodes
Reverse
Editor’s Choice Papers: What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women Editorial: Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approachHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Ann Oluloro, MD, MPH, University of WashingtonEloise Chapman-Davis, MD, Weill Cornell Medicine
Editor’s Choice Paper:Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study
Editorial:Sentinel lymph node biopsy in high-risk endometrial cancer: The dénouement
Hosted by:Gregg Nelson, MD, Social Media Editor of Gynecologic OncologyFeaturing:Sarah M. Bjørnholt, MD, Aarhus University Hospital, DenmarkSean Dowdy, MD, Mayo Clinic, USA
Editor’s Choice Paper: Experiences of patients with peritoneal carcinomatosis-related complex care needs and their caregivers Editorial:The importance of family-focused care in the setting of advanced gynecological cancersHosted by:Sean Dowdy, MD, Associate Editor of Gynecologic OncologyFeaturing:Rachel A. Pozzar, PhD, RN, Dana Farber Cancer Institute and Harvard Medical SchoolAllison J. Applebaum, PhD, Caregivers Clinic, Memorial Sloan Kettering Cancer Center
Editor’s Choice Paper: Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma Editorial:What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical CollegeGretchen Glaser, MD, Mayo Clinic John Weroha, MD, Mayo Clinic
Editor’s Choice Paper: Use of a mobile health patient engagement technology improves perioperative outcomes in gynecologic oncology patients Editorial:How does mobile health engagement technology help gynecologic oncology patients recover from surgery, affect health equity, and impact healthcare costs?Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic OncologyFeaturing:Teresa K.L. Boitano, MD, University of Alabama at BirminghamKevin M. Elias, MD, FACOG, FACS, Brigham and Women’s Hospital
Editor’s Choice Paper: Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer Hosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center
Editor’s Choice Paper: Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis? Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Amanika Kumar, MD, Mayo Clinic Laura Havrilesky, MD, Duke University
Editor’s Choice Papers: Improving genetic testing following abnormal mismatch repair immunohistochemistry results in endometrial cancerEditorial: Universal testing – Should it be that hard? Probably. If you're doing it rightHosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Bhavana Pothuri, MD,NYU Perlmutter Cancer CenterLeigha Senter, MS, CGC, The Ohio State University College of Medicine
Editor’s Choice Papers: Detection of endometrial cancer using tampon-based collection and methylated DNA markersEditorial: Early detection of endometrial cancerHosted by:Dineo Khabele, MD, Associate Editor of Gynecologic Oncology Featuring:Jamie N. Bakkum-Gamez, MD, Mayo ClinicJonathan C. Dudley, MD, The Johns Hopkins University School of Medicine
TKI Toxicities: A Society of Gynecologic Oncology Podcast Moderator:Róisín O’Cearbhaill, MD, Gynecologic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York Speakers: BJ Rimel, MD, Gynecologic Oncologist, Cedars-Sinai Medical CenterErin Crane, MD, MPH, Gynecologic Oncologist, Levine Cancer InstituteVicky Makker, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center Jennifer MacDonald, PharmD, Oncology Clinical Pharmacy Specialist, Medical University of South Carolina Róisín O’Cearbhaill, MD, is joined by BJ Rimel, MD, Erin Crane, MD, MPH, Vicky Makker, MD, and Jennifer McDonald, PharmD, to review the clinical management of tyrosine kinase inhibitors (TKIs) in gynecologic cancers with consideration for dose adjustments and modifications. The speakers discuss the optimal management of commonly encountered toxicities, such as hypertension and hypothyroidism, that are associated with several of the TKIs. They also highlight management strategies, patient reference materials and anticipatory prescriptions for antihypertensives, antidiarrheals, and antiemetics. The podcast includes two patient cases that delve into information about the differences in toxicities between lenvatinib and pazopanib, hypertension and which drugs to use in which order (both starting dose and dose adjustments), and medical access and lab intervals. These practical clinical pearls in managing toxicities aim to guide practitioners on how best to use these drugs to treat gynecologic cancers. This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology. Additional Resources: Tyrosine kinase inhibitor toxicities: A Society of Gynecologic Oncology review and recommendations Download audio Browse all Gynecologic Oncology audio
Editor’s Choice Papers: Enhanced recovery after surgery (ERAS reg) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update Editorial: Gynecologic oncology surgery – Ready for the next step in ERASHosted by:Amanda Nickles Fader, MD, Associate Editor of Gynecologic Oncology Featuring: Gregg Nelson, MD, University of CalgarySean Dowdy, MD, Mayo Clinic College of MedicineOlle Ljungqvist, MD, Orebro University Hospital
Editor’s Choice Papers: Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report Editorial: “The times they are a-changin’” – And how are we managing?Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology Featuring: Stephanie V. Blank,MD, Icahn School of Medicine at Mount SinaiWarner K. Huh, MD, FACOG, FACS, University of Alabama Birmingham
Editor’s Choice Papers: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center study Editorial: Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: The evolution of a “pelvic” surgeon Hosted by:Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology Featuring: Ryan M. Kahn MD,FACOG, Memorial Sloan Kettering Cancer Center Dennis Chi, MD, Memorial Sloan Kettering Cancer CenterProf Christina Fotopoulou, Imperial College London, UK
Hosted by:Wendy R. Brewster, MD, PhD, Deputy Editor of Gynecologic Oncology Featuring:Turgay Ayer, Georgia Institute of TechnologyTara Castellano, MD, Louisiana State University HSCIsabel C. Scarinci, PhD, MPH, University of Alabama at Birmingham Editor’s Choice Paper: Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer Editorial: Targeting our efforts: the contribution of an open-access tool to assess geographic distribution of recurrent and metastatic cervical cancer
Editor’s Choice Papers: Sentinel lymph node mapping in patients with endometrial hyperplasia: A practice to preserve or abandon? Is sentinel lymph node assessment useful in patients with a preoperative diagnosis of endometrial intraepithelial neoplasia? Editorial: Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment? Hosted by:Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring: Jennifer Mueller MD, Memorial Sloan Kettering Cancer CenterEmad Matanes MD, Rambam Medical CenterEmma Rossi MD, Duke University Medical Center
Moderator: Kari Hacker, MD, PhD, Gynecologic Oncologist, New York University Langone Health Speakers: Christine Walsh, MD, MS, Gynecologic Oncologist, University of ColoradoCarolyn McCourt, MD, Gynecologic Oncologist, Washington University School of Medicine Kari Hacker, MD, PhD, is joined by Christine Walsh, MD, MS, and Carolyn McCourt, MD, to review basic molecular classification as well as more complex biomarkers in endometrial cancer. They discuss how testing can be utilized to inform patient prognosis and to guide second line systemic treatment decisions. They also highlight several ongoing trials investigating treatment strategies based on molecular features, the results of which will help clinicians make better therapeutic decisions, resulting in better outcomes for patients with endometrial cancer. This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Additional Resources: Molecular testing for endometrial cancer: An SGO clinical practice statement
Hosted by: Gregg Nelson, MD, PhD, Social Media Editor of Gynecologic Oncology Featuring:Brittany A. Davidson, MD, Duke UniversityDavid M. Kushner, MD, UW School of Medicine and Public Health Article: SGO and the elephant that is still in the room: Wellness, burnout and gynecologic oncology
Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorial Featuring: David O'Malley, MD, The Ohio State University Editor’s Choice Paper: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma Editorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data
Hosted by: Amanda Nickles Fader, MD, Associate Editor of Gynecologic OncologyFeaturing:David M. Gershenson, MD, The University of Texas MD Anderson Cancer CenterCharlie Gourley, MD, Nicola Murray Centre for Ovarian Cancer ResearchEditor’s Choice Paper: Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival Editorial: Low grade serous ovarian cancer: Unpicking drivers of outcome
Hosted by: S. Diane Yamada, MD, Deputy Editor of Gynecologic OncologyFeaturing:Maaike Oonk, MD, University Medical Center Groningen, University of Groningen, The NetherlandsAkila Viswanathan, MD, MPH, Johns Hopkins MedicineEditor’s Choice Paper: Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe Editorial: When is it safe to omit contralateral groin management in unilateral sentinel node-positive early stage vulvar cancer?
Comments
Download from Google Play
Download from App Store
United States